Compare Oatly Group AB - ADR (OTLY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Recursion Pharmaceuticals Inc — how do they compare? Oatly Group AB - ADR trades at $10.86 (market cap $282.27M), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.8× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| OTLY | RXRX | |
|---|---|---|
Market Cap | $282.27M | $1.63B |
Sector | Consumer Staples | Health |
52-Week High | $18.54 | $6.79 |
52-Week Low | $8.03 | $2.84 |
Enterprise Value | $779.89M | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $9.05, down 9.86% in the last session, with a neutral technical signal. The company shows modest revenue growth to $862M in 2025 but continues to report significant losses with a -17.06% net margin. Cash flow remains negative at -$35M, though improving from previous years. Recent news highlights new product launches and upcoming Q2 2026 earnings on July 22.
The outlook remains challenging with persistent losses and high debt levels creating financial strain. Analyst sentiment is mixed with 44% buy ratings but 50% hold, reflecting uncertainty about profitability timeline. Key risks include cash burn sustainability and competitive pressure in the plant-based beverage market.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
